Dermorphin Research: Chemistry, D-Amino-Acid Biology and Analytical Detection

What is dermorphin?

What is dermorphin? A naturally occurring heptapeptide isolated from the skin of South American tree frogs of the genus Phyllomedusa. Montecucchi and colleagues reported its isolation from methanol extracts of Phyllomedusa sauvagei skin and its full sequence in the International Journal of Peptide and Protein Research in 1981 (PMID 7287299). The sequence is Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂: seven residues, a free N-terminal tyrosine, a C-terminal serine amide, and — the feature everything else follows from — a D-alanine at position two.

The 1981 paper describes the peptide as presenting striking differences from the enkephalins known at the time, and calls it a surprising example of a peptide from Vertebrata containing a D-amino acid residue in its sequence. That understates it slightly. Proteins and peptides in animals are built from L-amino acids; the ribosome has no mechanism for inserting a D-residue. A vertebrate peptide containing one was, in 1981, a chemical anomaly with no explanation.

This page is a chemical and analytical reference for people working with the compound as a research material. It contains no dosing, no reconstitution procedure, no route, no application and no statement about what the compound does in any organism outside the specific published experiments described below.

Discovery and origin in the literature

Frog skin as a peptide library

The Phyllomedusa skin secretions turned out to contain a whole family of opioid-active peptides, not one. Erspamer and colleagues reported in PNAS in 1989 (PMID 2544892) a related group they named the deltorphins, characterised by high affinity and selectivity for delta opioid binding sites rather than mu — and these also contain a D-residue. Negri and colleagues (1992, PMID 1353890) then characterised three naturally occurring dermorphin-like peptides from Phyllomedusa bicolor together with their C-terminal amides and substituted analogues. The practical point for anyone reading this literature is that “dermorphin” names one specific sequence within a family of closely related ones, several of which differ by a single residue.

The 1987 result: where the D-alanine comes from

The anomaly was resolved by Richter, Egger and Kreil in Science in 1987 (PMID 3659910), and the experiment is worth describing because it is clean. They built cDNA libraries from frog skin messenger RNA and screened them with oligonucleotides encoding part of the dermorphin sequence. The clones they recovered encoded dermorphin precursors containing homologous 35-amino-acid repeats, each carrying one copy of the heptapeptide. At the position where the finished peptide carries D-alanine, the cDNA carried the ordinary L-alanine codon GCG.

The conclusion is unavoidable: the gene encodes an all-L peptide, and the D-residue is generated afterwards. The paper proposed a novel post-translational reaction converting an L-amino acid to its D-isomer — what is now understood as peptide isomerase chemistry, and a genuine addition to the catalogue of post-translational modifications. Related work on the precursor followed, including Seethaler and colleagues (1991, J Cell Biol, PMID 1894691) showing that frog prodermorphin could be targeted to the regulated secretory pathway in mammalian cells by fusion to proenkephalin.

Reference data

From the public chemical record (PubChem CID 5485199) and the 1981 sequencing paper.

Two rows in that table are the ones a purchaser should read twice. The stereochemistry row defines the molecule and is the hardest thing to verify. The regulatory row is not a formality: this is an opioid peptide with a documented misuse history, and the legal position on possession and handling differs by jurisdiction. Establishing that position is the responsibility of whoever holds the material. No handling quantity, reconstitution procedure or route is given or implied on this page.

Receptor pharmacology as reported in the literature

• Mu-opioid receptor selectivity. Negri et al. (1992) determined opioid binding profiles for dermorphin-related peptides and their amidated analogues, reporting very high selectivity for mu sites. Within the mu class the same data suggested two subtypes of high and low affinity — a distinction the authors then probed with ligands preferring one or the other.
• Isolated-organ preparations. The same study reported that the peptides acted as agonists in guinea-pig ileum and mouse vas deferens preparations, with substantially greater activity in the former. These are the classical bioassays of opioid pharmacology, and they measure inhibition of electrically evoked contractions in excised tissue.
• Subtype-dependent behavioural readouts in rats. Negri et al. reported that the high-affinity-site-preferring analogue and the low-affinity-site-preferring analogue produced different profiles in rats — the latter producing intense catalepsy alongside weak antinociception. This is cited here as receptor-subtype pharmacology, which is what the paper is about; it is not an application and not a recommendation.
• Structure–activity is stereochemistry-dependent. The D-residue at position two is not decorative. Across the opioid-peptide literature, D-substitution at position two is a recurring design element in synthetic analogues because it changes both receptor interaction and susceptibility to peptidases; in dermorphin nature arrived there first, by a post-translational route.

Every item above describes what was measured in a named preparation by a named group. None of it is a statement about effects in a person, and nothing on this page should be read as one.

Metabolism, detection and the doping-control literature

The most active recent literature on dermorphin is analytical, and it exists for a specific reason: the compound was misused in horse racing, and laboratories needed to be able to find it.

Equine plasma detection

Wang and colleagues (2014, Drug Testing and Analysis, PMID 23720224) developed an LC-MS/MS method for dermorphin and HYP⁶-dermorphin in equine plasma, prompted by the classification of dermorphin as a Class 1 drug by Racing Commissioners International — the most restrictive category, meaning a banned substance in equine athletes. Their procedure extracted 2 mL of plasma on a mixed-mode cation-exchange solid-phase column, then separated and detected both analytes by triple-quadrupole linear ion-trap mass spectrometry in positive multiple-reaction-monitoring mode, using four MRM transitions per compound for identification, with a total run time of 3.5 minutes. The paper reports it as the first method for these analytes in equine plasma.

Metabolism, and what a laboratory should actually look for

de L Castro and colleagues (2021, Current Drug Metabolism, PMID 33593255) addressed the human-doping-control question by studying dermorphin metabolism in two model systems — human liver microsomes and a zebrafish water-tank model. They proposed six putative metabolites from exact-mass measurements and identified the N-terminal tetrapeptide YAFG-OH (m/z 457.2085) as the major metabolite in both systems, consistent with earlier rat work. Their conclusion is a practical one for analysts: because that metabolite is well characterised and commercially available, it is a suitable primary target analyte for detecting dermorphin misuse, with the other metabolites serving as confirmatory markers.

For a research laboratory, those two papers are the most directly useful items in the whole dermorphin literature. They describe, in reproducible detail, how the compound and its breakdown products are identified in a biological matrix.

Research models and evidence status

What the record contains

A well-established isolation and sequence (1981), a resolved and genuinely notable biosynthetic question (1987), a solid mu-receptor binding and isolated-organ characterisation (1989–1992), precursor cell-biology work (1991–1993), and a modern analytical-chemistry strand driven by doping control (2014–2021). By the standards of most compounds in this catalogue that is a real, coherent literature, mostly built by Italian and Austrian groups over a decade and then picked up by forensic laboratories.

What is not established

There are no registered clinical trials of dermorphin — a ClinicalTrials.gov search returns zero studies. It is not an approved medicine anywhere we could source, and there is no published human pharmacokinetic, safety or tolerability dataset. The receptor-subtype interpretation from the 1992 binding work belongs to its era of opioid pharmacology and has not, so far as indexed sources show, been revisited with modern receptor-structure methods. The natural-product literature largely stops in the 1990s; what continued is the analytical work.

It is also worth being explicit about what the doping literature does and does not tell a reader. That laboratories built detection methods establishes that the compound was being administered to animals in competition and that authorities acted to stop it. It does not establish any property of the compound in a person, and it is not a description of use. It is cited here because it is the best-documented analytical chemistry available for this molecule.

Nothing on this page is a claim about what this compound does in a person. This page makes no efficacy, therapeutic, analgesic or other use claim of any kind, provides no dosing, handling or preparation guidance, and the material is supplied for laboratory research use only — not for human or veterinary use.

How to verify this compound yourself

Dermorphin is the clearest case in this library of a compound where a routine certificate of analysis cannot fully establish identity, and the reason is worth understanding rather than glossing.

• Mass spectrometry cannot see stereochemistry. D-alanine and L-alanine have identical molecular formulas and identical masses. An all-L version of this sequence — a different molecule with different receptor behaviour — would return the same mass spectrum as the correct compound. Mass spec confirms composition, not configuration.
• Ordinary HPLC cannot resolve it either. On the achiral reversed-phase columns used for routine peptide purity, the two diastereomeric peptides may separate slightly or may not; nothing about a single symmetric peak proves which one eluted. Establishing the D-configuration requires chiral analysis — chiral chromatography, or hydrolysis followed by chiral amino-acid analysis — and that is not part of a standard peptide COA. The same limitation, in a more extreme form, is explained on our FOXO4-DRI page, where every residue is a D-amino acid and the entire design premise is invisible to routine analysis.
• What a COA does establish. Mass-spec identity separates dermorphin (≈803 Da) from its close natural relatives and from HYP⁶-dermorphin, which differs by a single oxygen (16 Da) — a difference that is unambiguous on a mass spectrum and invisible on a label. HPLC purity on a seven-residue synthesis is a meaningful number, though a short peptide is comparatively easy to make cleanly.
• Ask the supplier the stereochemistry question directly. A supplier synthesising this sequence must deliberately incorporate D-Ala at position two, which means the information exists at the synthesis stage even when it does not appear on the certificate. Asking what analytical evidence supports the configuration — rather than assuming the label covers it — is the single most useful question about this compound.
• Counter-ion documentation — usually trifluoroacetate, affecting net peptide content per unit mass. A documentation question, not a purity failure.

See how to read a COA for what each certificate line means, and how to verify peptide purity for how the analytical methods fit together and where they stop. The exact batch received can be checked on the self-serve verify tool.

Research-grade sourcing and verification

Dermorphin is listed on our sourcing catalogue. For laboratory research use only, material is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation, verifiable at the lot level — with the stereochemical limitation described above stated plainly rather than glossed over. Because this compound is an opioid peptide and a controlled substance in at least one regulated context, establishing the legal position for possession, import and handling in a given jurisdiction is the responsibility of the receiving laboratory. For the companion page on why enantiomeric chemistry defeats routine analysis, see FOXO4-DRI research; for the analytical methods generally, see how to verify peptide purity. This is sourcing and quality-assurance framing only.

Frequently asked questions

Literature cited

1. Montecucchi PC, de Castiglione R, Piani S, Gozzini L, Erspamer V. “Amino acid composition and sequence of dermorphin, a novel opiate-like peptide from the skin of Phyllomedusa sauvagei.” Int J Pept Protein Res. 1981;17(3):275–283. PMID 7287299. pubmed.ncbi.nlm.nih.gov/7287299. The isolation and sequence.
2. Richter K, Egger R, Kreil G. “D-alanine in the frog skin peptide dermorphin is derived from L-alanine in the precursor.” Science. 1987;238(4824):200–202. PMID 3659910. pubmed.ncbi.nlm.nih.gov/3659910. The post-translational isomerisation result.
3. Erspamer V, Melchiorri P, Falconieri-Erspamer G, et al. “Deltorphins: a family of naturally occurring peptides with high affinity and selectivity for delta opioid binding sites.” Proc Natl Acad Sci U S A. 1989;86(13):5188–5192. PMID 2544892. pubmed.ncbi.nlm.nih.gov/2544892 (the related delta-selective family).
4. Seethaler G, Chaminade M, Vlasak R, et al. “Targeting of frog prodermorphin to the regulated secretory pathway by fusion to proenkephalin.” J Cell Biol. 1991;114(6):1125–1133. PMID 1894691. pubmed.ncbi.nlm.nih.gov/1894691.
5. Negri L, Erspamer GF, Severini C, Potenza RL, Melchiorri P, Erspamer V. “Dermorphin-related peptides from the skin of Phyllomedusa bicolor and their amidated analogs activate two mu opioid receptor subtypes that modulate antinociception and catalepsy in the rat.” Proc Natl Acad Sci U S A. 1992;89(15):7203–7207. PMID 1353890. pubmed.ncbi.nlm.nih.gov/1353890.
6. Wang CC, Hartmann-Fischbach P, Krueger TR, Wells TL, Feineman AR, Compton JC. “Fast and sensitive analysis of dermorphin and HYP6-dermorphin in equine plasma using liquid chromatography tandem mass spectrometry.” Drug Test Anal. 2014;6(4):342–349. PMID 23720224. pubmed.ncbi.nlm.nih.gov/23720224. Source of the RCI Class 1 classification.
7. de L Castro J, Pereira HMG, de Sousa VP, Martucci MEP. “Evaluation of Dermorphin Metabolism Using Zebrafish Water Tank Model and Human Liver Microsomes.” Curr Drug Metab. 2021;22(5):372–382. PMID 33593255. pubmed.ncbi.nlm.nih.gov/33593255. Source of the YAFG-OH metabolite identification.
8. National Center for Biotechnology Information. “PubChem Compound Summary for CID 5485199, Dermorphin.” pubchem.ncbi.nlm.nih.gov/compound/5485199 (formula, mass, CAS 77614-16-5, sequence).